# Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

> **NCT01969318** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 120 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Placebo /Metformin
- **DRUG:** SP2086(50 mg q.d.)/Metformin
- **DRUG:** SP2086 (100 mg q.d.)/Metformin

## Key facts

- **NCT ID:** NCT01969318
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2013-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01969318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01969318, "Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01969318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*